VIVELLE-DOT (Transdermal)

By /

VIVELLE-DOT (Transdermal Estradiol Patch) — Comprehensive Medical Review

Uses & Indications

VIVELLE-DOT is a prescription transdermal patch that delivers estradiol, the primary female estrogen hormone, through the skin directly into the bloodstream. It is indicated for:

  • Treatment of moderate to severe vasomotor symptoms (hot flashes, night sweats) related to menopause:
    Menopause results in a marked decline in circulating estrogen levels causing vasomotor instability, leading to hot flashes, sweating, and sleep disturbances. VIVELLE-DOT replaces deficient estrogen to restore thermoregulatory balance.
  • Prevention of postmenopausal osteoporosis:
    Estrogen deficiency leads to increased bone resorption and risk of fractures. VIVELLE-DOT maintains bone density by inhibiting osteoclast-mediated bone breakdown.
  • Treatment of hypoestrogenism due to ovarian failure or removal:
    Women who have premature ovarian insufficiency or surgical menopause experience early estrogen deficiency that can be managed with VIVELLE-DOT.
  • Management of atrophic vaginitis and urogenital atrophy symptoms:
    Estrogen supports vaginal mucosa integrity, lubrication, and urinary tract health.
  • Certain cases of menstrual irregularities or hormonal imbalances:
    Used off-label in some cases to regulate cycles when indicated.

The patch offers an advantage over oral estrogen formulations by avoiding first-pass liver metabolism, leading to steadier plasma hormone levels and reduced hepatic side effects such as clotting factor induction.

Mechanism of Action

Estradiol is the most potent natural estrogen and binds to estrogen receptors alpha and beta located in multiple tissues including reproductive organs, bone, brain, liver, and cardiovascular system. Through these receptors, estradiol modulates gene expression affecting cellular function and physiology.

Key effects include:

  • Central Nervous System:
    Estradiol regulates the hypothalamic thermoregulatory center to reduce hot flashes and night sweats.
  • Bone:
    It inhibits osteoclast activity, reducing bone resorption, and promotes osteoblast activity for bone formation, preserving bone density.
  • Reproductive Tract:
    Supports vaginal epithelial cell proliferation, mucus secretion, and maintains urethral sphincter tone, preventing dryness, irritation, and urinary symptoms.
  • Cardiovascular:
    Improves lipid profiles by increasing HDL and lowering LDL cholesterol; promotes vasodilation via nitric oxide pathways.
  • Liver:
    Regulates synthesis of proteins involved in coagulation and metabolism.
  • Skin:
    Maintains collagen content and skin elasticity.

Transdermal delivery allows estradiol to be absorbed directly into systemic circulation, bypassing first-pass hepatic metabolism. This results in:

  • More stable serum estradiol levels without the peaks and troughs of oral dosing.
  • Reduced stimulation of hepatic protein synthesis (including clotting factors, binding globulins, and triglycerides), which translates into lower risk of thromboembolic events and lipid abnormalities.

Pharmacokinetics

  • Absorption:
    Estradiol is released continuously from the patch matrix and absorbed through the epidermis into the dermal capillaries.
  • Distribution:
    Circulates bound primarily to sex hormone-binding globulin (SHBG) and albumin.
  • Metabolism:
    Metabolized mainly in the liver to estrone and estriol, which have weaker estrogenic activity.
  • Elimination:
    Excreted in urine and feces as conjugates.
  • Half-life:
    Approximately 27 hours, allowing twice-weekly patch changes.

Dosage and Administration

Patch Strengths and Dosing Regimens:

  • Available in multiple strengths delivering 0.025 mg, 0.0375 mg, 0.05 mg, 0.075 mg, or 0.1 mg of estradiol per day.
  • Usually applied twice weekly (every 3-4 days) to maintain consistent hormone levels.

Application Instructions:

  • Site Selection:
    Choose clean, dry, intact, non-irritated skin areas on the lower abdomen or buttocks. Avoid breasts and areas prone to excessive movement or friction.
  • Application Technique:
    1. Wash and dry hands before handling the patch.
    2. Remove patch from protective pouch and peel off backing carefully without touching adhesive.
    3. Press firmly to skin for about 10 seconds, ensuring full contact.
    4. Do not cut or alter the patch.
    5. Rotate application sites with each patch change to minimize irritation.
  • Water Exposure:
    The patch is water-resistant; normal bathing, showering, or swimming does not affect adhesion when applied properly.
  • Missed Patch:
    If patch falls off or replacement is delayed:
    • Apply new patch as soon as possible.
    • If more than 24 hours have passed without a patch, contact your healthcare provider for guidance.
    • Avoid reusing the old patch.
  • Concurrent Progestin:
    For women with an intact uterus, a progestin is prescribed concurrently or cyclically to reduce the risk of endometrial hyperplasia.

Clinical Efficacy

  • Vasomotor Symptoms:
    Numerous clinical trials demonstrate significant reduction in frequency and severity of hot flashes and night sweats within 1-2 weeks of therapy initiation.
  • Bone Mineral Density:
    Long-term use preserves or increases bone density, reducing fracture risk, especially in the spine and hip.
  • Urogenital Health:
    Improvement in vaginal epithelial thickness, lubrication, and reduction in urinary tract infections.
  • Quality of Life:
    Improvements in sleep quality, mood stabilization, and sexual function.

Side Effects

Local Reactions:

  • Application site reactions such as redness, itching, burning, or rash occur in approximately 10-20% of users, usually mild and transient.

Systemic Side Effects:

  • Breast tenderness or enlargement
  • Nausea, vomiting, abdominal bloating or cramping
  • Headache or migraine exacerbation
  • Mood changes including depression, irritability, anxiety
  • Weight gain or fluid retention
  • Menstrual irregularities, spotting, or breakthrough bleeding
  • Increased blood pressure in some patients

Serious Adverse Effects:

  • Thromboembolism: Deep vein thrombosis, pulmonary embolism risks are increased, particularly in women with predisposing factors (smoking, obesity, age >35).
  • Stroke and Myocardial Infarction: Increased risk, especially in smokers and older patients.
  • Breast and Endometrial Cancer: Long-term estrogen exposure, particularly without adequate progestin, raises cancer risks.
  • Gallbladder Disease: Increased risk of cholelithiasis and cholecystitis.
  • Liver Dysfunction: Cholestasis or hepatic adenomas (rare).

Contraindications

  • Known or suspected pregnancy
  • Undiagnosed abnormal vaginal bleeding
  • Known or suspected estrogen-dependent neoplasia
  • Active or history of thromboembolic disorders
  • Active liver disease or dysfunction
  • Hypersensitivity to estradiol or any patch components

Warnings and Precautions

  • Cardiovascular Risk: Careful assessment of personal and family history of cardiovascular disease is necessary.
  • Cancer Screening: Regular breast and pelvic exams recommended.
  • Smoking: Strongly discouraged due to additive risks.
  • Progestin Therapy: Required for women with intact uterus to prevent endometrial hyperplasia.
  • Liver and Kidney Impairment: Monitor closely, adjust therapy as needed.
  • Mental Health: Monitor patients with a history of depression or mood disorders.
  • Surgery/Immobilization: Consider discontinuation during prolonged immobilization due to thromboembolism risk.

Drug Interactions

  • Enzyme Inducers: Carbamazepine, phenytoin, phenobarbital, rifampin, and St. John’s Wort may reduce estradiol efficacy by inducing hepatic metabolism.
  • Anticoagulants: Estrogens may alter anticoagulant effects.
  • Other Hormones: Co-administration with other hormonal therapies requires monitoring for additive effects.
  • CYP3A4 Inhibitors: May increase estradiol plasma levels, increasing side effect risk.

Patient Counseling

  • Proper application technique and site rotation to minimize irritation.
  • Use the lowest effective dose for shortest duration possible.
  • Do not smoke; lifestyle modification reduces risks.
  • Report any unusual symptoms such as leg pain, chest pain, vision changes, or severe headaches immediately.
  • Maintain scheduled follow-up appointments for screening and monitoring.
  • Avoid use during pregnancy or breastfeeding without medical advice.
  • Be aware of potential mood changes and seek help if needed.

Monitoring Parameters

  • Baseline and periodic blood pressure
  • Liver function tests if clinically indicated
  • Mammography and breast exams per guidelines
  • Bone mineral density assessments in long-term users
  • Evaluation for thromboembolic risk factors

Frequently Asked Questions (FAQs)

Q1: How soon will I notice symptom improvement?
A: Hot flashes and night sweats may improve within 1-2 weeks; maximum benefit typically seen after 4-6 weeks.

Q2: Can I swim or shower with the patch on?
A: Yes, the patch is water-resistant when properly applied.

Q3: What should I do if my patch falls off?
A: Apply a new patch immediately; if over 24 hours have passed, consult your doctor.

Q4: Is this therapy safe for long-term use?
A: Long-term use requires medical supervision to balance benefits with risks like cancer and cardiovascular disease.

Q5: Can I use this patch for contraception?
A: No, VIVELLE-DOT is not approved as a contraceptive.

References

  1. U.S. Food and Drug Administration. VIVELLE-DOT (estradiol transdermal system) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021463s024lbl.pdf
  2. North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement. Menopause. 2013;20(9):888–902.
  3. Santen RJ et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95(7 Suppl 1):s1-66.
  4. Mayo Clinic. Hormone Replacement Therapy (HRT). https://www.mayoclinic.org/tests-procedures/hormone-replacement-therapy/about/pac-20385100
  5. MedlinePlus. Estradiol Transdermal Patch. https://medlineplus.gov/druginfo/meds/a601065.html

Table of Contents

→ Index
Scroll to Top